Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials

Reuss, Joshua E.; Stern, Diana; Foster, Jared C.; Ramaswami, Ramya; Lurain, Kathryn; Chen, Alice; Streicher, Howard; Kem, Ravie; Little, Richard F.; Sharon, Elad

doi:10.1001/jamanetworkopen.2020.27110

Cited by 18 publications

(16 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPV was detected in all the specimens tested in this study, given its high prevalence in SCCA [56]. Therefore, nivolumab has shown an encouraging therapeutic effect in patients with HPV-associated cancer and is worthy of further evaluation in these patients [57]. Ho et al (2018) published a case report that described a robust response to combined therapy with ICIs in HPV-related small cell cancer.…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 79%

See 1 more Smart Citation

Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review

Almeida

Ribeiro

Raposo

et al. 2021

Viruses

View full text Add to dashboard Cite

Immunotherapy has been shown to be highly effective in some types of cancer caused by viruses. Gene therapy involves insertion or modification of a therapeutic gene, to correct for inappropriate gene products that cause/may cause diseases. Both these types of therapy have been used as alternative ways to avoid cancers caused by oncoviruses. In this review, we summarize recent studies on immunotherapy and gene therapy including the topics of oncolytic immunotherapy, immune checkpoint inhibitors, gene replacement, antisense oligonucleotides, RNA interference, clustered regularly interspaced short palindromic repeats Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene editing, transcription activator-like effector nucleases (TALENs) and custom treatment for Epstein–Barr virus, human T-lymphotropic virus 1, hepatitis B virus, human papillomavirus, hepatitis C virus, herpesvirus associated with Kaposi’s sarcoma, Merkel cell polyomavirus, and cytomegalovirus.

show abstract

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 79%

Section: Immunotherapymentioning

confidence: 99%

Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review

Almeida

Ribeiro

Raposo

et al. 2021

Viruses

View full text Add to dashboard Cite

show abstract

“…As stated above, this exclusion was due to the fear of side effects related to reestablishing the immunity against HIV and to the concern that this population lacks a sufficient underlying T-cell immunity to benefit from therapy. In the last few years, encouraging trends in the inclusion of PLWHIV in ICI trials have been identified [51,52]. These data have already been collected in a small number of reviews [40][41][42] assessing the safety and efficacy of ICIs in this subgroup of patients with advanced cancer.…”

Section: Safety and Efficacy Of Icis In Plwhivmentioning

confidence: 99%

“…Even though PLWHIV are at increased risk of developing several cancers, this population has been historically excluded from clinical trials assessing the efficacy of ICIs, thus inhibiting broad implementation of these therapies among PLWHIV with cancer [ 51 ]. As stated above, this exclusion was due to the fear of side effects related to reestablishing the immunity against HIV and to the concern that this population lacks a sufficient underlying T-cell immunity to benefit from therapy.…”

Section: Safety and Efficacy Of Icis In Plwhivmentioning

confidence: 99%

Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies

Castelli

Lombardi

Palomba

et al. 2021

Cells

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) are reshaping the landscape of cancer treatment, redefining the prognosis of several tumors. They act by restoring the cytotoxic activity of tumor-specific T lymphocytes that are in a condition of immune exhaustion. The same condition has been widely described in chronic HIV infection. In this review, we dissect the role of ICIs in people living with HIV/AIDS (PLWHIV). First, we provide an overview of the immunologic scenario. Second, we discuss the possible use of ICIs as adjuvant treatment of HIV to achieve elimination of the viral reservoir. Third, we examine the influence of HIV infection on ICI safety and effectiveness. Finally, we describe how the administration of ICIs impacts opportunistic infections.

show abstract

“…Healthcare disparities,2 and lack of knowledge of the safety and efficacy of cancer immunotherapy among PWH, limit access to treatment on this population at risk. Despite the recommendation from the American Society of Clinical Oncology supporting the inclusion of PWH in cancer clinical trials,14 a recent study found that 72.9% of recent cancer immunotherapy trials specifically exclude PWH 15. The data on the use of immunotherapy in PWH diagnosed with cancer are scarce.…”

Section: Introductionmentioning

confidence: 99%

Cancer Immunotherapy in Adult Patients with HIV

Khalaf

Dandachi

Granwehr

et al. 2022

Journal of Investigative Medicine

View full text Add to dashboard Cite

The availability of antiretroviral therapy (ART) has increased the life expectancy of people with HIV (PWH) and reduced the incidence of AIDS-associated malignancies, yet PWH have a significantly increased incidence of malignancy and less favorable outcomes of cancer treatment compared with the general population.Immunotherapy has revolutionized cancer therapy, becoming the standard of care for various malignancy treatments. However, PWH are an underserved population with limited access to clinical trials and cancer treatment.This review of the available evidence on different classes of cancer immunotherapy in PWH is mostly based on case reports, case series, but few prospective studies and clinical trials due to the exclusion of PWH from most oncologic clinical trials. The results of the available evidence support the safety of immunotherapy in PWH. Immunotherapy has similar effectiveness in PWH, an acceptable toxicity profile, and has no clinically significant impact on HIV viral load and CD4-T cell count. In addition, there is no reported change in the incidence of opportunistic infections and other complications for PWH with well-controlled viremia.This review aims to briefly summarize the current state of immunotherapy in cancer, guide clinicians in the management of immunotherapy in cancer PWH, and encourage the inclusion of PWH in clinical trials of cancer immunotherapy.

show abstract

Assessment of Cancer Therapy Evaluation Program Advocacy and Inclusion Rates of People Living With HIV in Anti–PD1/PDL1 Clinical Trials

Cited by 18 publications

References 16 publications

Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review

Immunotherapy and Gene Therapy for Oncoviruses Infections: A Review

Immune Checkpoint Inhibitors in People Living with HIV/AIDS: Facts and Controversies

Cancer Immunotherapy in Adult Patients with HIV

Contact Info

Product

Resources

About